The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJohnson Matthey Regulatory News (JMAT)

Share Price Information for Johnson Matthey (JMAT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,804.00
Bid: 1,813.00
Ask: 1,816.00
Change: 14.00 (0.78%)
Spread: 3.00 (0.165%)
Open: 1,788.00
High: 1,827.00
Low: 1,770.00
Prev. Close: 1,790.00
JMAT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Johnson Matthey business update

7 Feb 2018 07:00

RNS Number : 0785E
Johnson Matthey PLC
07 February 2018
 

Johnson Matthey business update

 

Johnson Matthey today provides an update on two business matters: the settlement of the contract dispute lawsuit reported as a contingent liability in November 2017; and the positive impact of US tax legislation on the group.

Settlement of after treatment contract lawsuit

As announced on 21st November 2017, a group company, Johnson Matthey Inc. (JMI), had been made a defendant to a contract dispute lawsuit alongside a supplier to an automotive OEM in the United States. The dispute related to a component supplied by the group. We reported a contingent liability in relation to the lawsuit in the announcement of our half year results for the six months ended 30th September 2017.

 

Today we announce that the lawsuit against JMI has been settled on mutually acceptable terms with no admission of fault. Under this settlement agreement, Johnson Matthey will recognise a charge of £50 million in connection with resolution of the lawsuit. This charge will be excluded from underlying operating profit for the year ending 31st March 2018.

 

Positive impact of US tax legislation on Johnson Matthey

We note the approval of the US Tax Cuts and Jobs Act, which became generally effective 1st January 2018, and expect to be positively impacted by these changes.

 

The lowering of the US corporate tax rate leads to a revaluation of our US deferred tax liabilities, which we estimate will result in a £30 million one-off non-cash benefit in the income tax expense line in the income statement for the year ending 31st March 2018. This will be excluded from the tax on underlying profit.

 

For the current financial year to 31st March 2018, we anticipate no change to the effective tax rate on underlying profit. We continue to expect this to be around 18%. Looking forward to the financial year ending 31st March 2019 and beyond we expect these changes will reduce the effective tax rate on underlying profit by around two percentage points. We continue to work through the full impact and will give more detail in our preliminary announcement for the year ending 31st March 2018.

 

Outlook

Our outlook for the year ending 31st March 2018 remains unchanged.

 

Enquiries:

Analysts and investors:

Martin Dunwoodie +44 (0)20 7269 8241

Simon McGough +44 (0)20 7269 8235

Katharine Burrow +44 (0)20 7269 8444

Media:

Sally Jones +44 (0)20 7269 8407

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDTFMJTMBAMBIP
Date   Source Headline
25th Jul 20233:43 pmRNSHolding(s) in Company
24th Jul 202310:00 amRNSDirector Declaration
21st Jul 202310:23 amRNSDirector/PDMR Shareholding
20th Jul 20231:10 pmRNSResult of AGM
12th Jul 20234:00 pmRNSDirector/PDMR Shareholding
10th Jul 20237:00 amRNSHolding(s) in Company
5th Jul 20238:00 amRNSHolding(s) in Company
29th Jun 20238:00 amRNSHolding(s) in Company
27th Jun 20237:00 amRNSJohnson Matthey: Catalyst Technologies seminar
23rd Jun 20234:37 pmRNSHolding(s) in Company
22nd Jun 20236:23 pmRNSHolding(s) in Company
22nd Jun 202312:57 pmRNSDirector/PDMR Shareholding
20th Jun 20234:29 pmRNSHolding(s) in Company
14th Jun 20235:16 pmRNSHolding(s) in Company
14th Jun 20239:43 amRNSHolding(s) in Company
14th Jun 20239:34 amRNSHolding(s) in Company
12th Jun 20235:43 pmRNSHolding(s) in Company
12th Jun 20239:00 amRNSAnnual Financial Report
9th Jun 20234:18 pmRNSHolding(s) in Company
8th Jun 20233:05 pmRNSHolding(s) in Company
7th Jun 20233:59 pmRNSHolding(s) in Company
7th Jun 20232:39 pmRNSHolding(s) in Company
2nd Jun 20238:48 amRNSHolding(s) in Company
31st May 20233:58 pmRNSHolding(s) in Company
31st May 20233:45 pmRNSHolding(s) in Company
26th May 20233:19 pmRNSHolding(s) in Company
25th May 20237:00 amRNSDirectorate Change
25th May 20237:00 amRNSJohnson Matthey full year results
24th May 20234:29 pmRNSHolding(s) in Company
22nd May 202310:16 amRNSHolding(s) in Company
22nd May 20237:00 amRNSJohnson Matthey and Hystar strategic partnership
19th May 20233:07 pmRNSHolding(s) in Company
19th May 202312:39 pmRNSDirector/PDMR Shareholding
16th May 20234:16 pmRNSHolding(s) in Company
16th May 20232:49 pmRNSHolding(s) in Company
10th May 20239:39 amRNSHolding(s) in Company
3rd May 20237:00 amRNSJM announces sale of Diagnostic Services
26th Apr 20237:00 amRNSCompany Secretary Change
21st Apr 20237:00 amRNSDirector/PDMR Shareholding
14th Apr 20238:30 amRNSHolding(s) in Company
12th Apr 20234:56 pmRNSHolding(s) in Company
12th Apr 20234:45 pmRNSHolding(s) in Company
11th Apr 20238:30 amRNSHolding(s) in Company
5th Apr 20233:40 pmRNSHolding(s) in Company
29th Mar 20235:00 pmRNSHolding(s) in Company
16th Mar 20235:11 pmRNSDirector/PDMR Shareholding
15th Mar 20233:14 pmRNSHolding(s) in Company
14th Mar 20234:14 pmRNSHolding(s) in Company
14th Mar 202311:53 amRNSHolding(s) in Company
1st Mar 202312:40 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.